SCHEMBL2834474

SCHEMBL2834474

O=S(=O)(c1ccccc1C(F)(F)F)N(CCOc1nccc(N2CCC3(CCN(c4ccncc4)CC3)CC2)n1)C1CC1

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CTSS P25774 11/20 0.40
RORC P51449 1/20 0.37
CYP2D6 P10635 4/20 0.36
CYP1A2 P05177 3/20 0.36
HIF1A Q16665 3/20 0.36
CYP2C19 P33261 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2C9 P11712 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
ITGB3 P05106 3/20 0.35
ITGA2B P08514 3/20 0.35
TSHR P16473 3/20 0.35
ALDH1A1 P00352 1/20 0.33
MAPK1 P28482 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2836220 0.80 CYP2D6 (0.36) RORCCYP2D6CYP1A2HIF1ACYP2C19
SCHEMBL12342559 0.79 CYP2D6 (0.39) CYP2D6CYP1A2HIF1ACYP2C19CYP3A4
Hydrochloric Acid SCHEMBL2836680 0.79 CYP2D6 (0.39) CYP2D6CYP1A2HIF1ACYP2C19CYP3A4
SCHEMBL2833995 0.79 CYP2D6 (0.36) CYP2D6CYP1A2HIF1ACYP2C19CYP3A4
SCHEMBL2831850 0.77 RORC (0.37) CTSSRORC
SCHEMBL2836485 0.76 CYP3A4 (0.37) CYP2D6CYP1A2HIF1ACYP2C19CYP3A4
SCHEMBL2833938 0.76 CYP2D6 (0.39) CYP2D6CYP1A2HIF1ACYP2C19CYP3A4
SCHEMBL2832213 0.74 CYP3A4 (0.38) CYP2D6CYP1A2HIF1ACYP2C19CYP3A4
SCHEMBL12342579 0.72 TP53 (0.32)
SCHEMBL2832089 0.71 BDKRB1 (0.33) CYP2D6CYP1A2CYP3A4ITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356101-B1 PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2013-02-27 EP claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US claimed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US claimed
EP-2356101-B1 PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2013-02-27 EP disclosed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds ADORA2B, CCNB1, TYMS CTSS 2788/4885RORC 2001/4885CYP2D6 1157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.